Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Bluebird Bio's Buyout Saga: Bankruptcy Looms as Shareholders Hesitate

Bluebird Bio's Buyout Saga: Bankruptcy Looms as Shareholders Hesitate

Bluebird bio, once a high-flying gene therapy pioneer, finds itself at a critical juncture as shareholders drag their feet on a proposed buyout, potentially pushing the company to the brink of bankruptcy. The Massachusetts-based biotech's struggle highlights the challenges facing innovative yet financially strained companies in the pharmaceutical sector.

NoahAI News5/14/2025
Novo Nordisk's Sogroya Shows Promise in Pediatric Growth Disorders

Novo Nordisk's Sogroya Shows Promise in Pediatric Growth Disorders

Novo Nordisk has unveiled promising results from its phase 3 REAL8 trial, demonstrating that its once-weekly human growth hormone analogue Sogroya is comparable to its daily predecessor, Norditropin, in treating multiple pediatric growth disorders. This development marks a significant step forward in the company's rare disease strategy and could potentially reshape treatment options for children with growth-related conditions.

NoahAI News5/14/2025
GSK Terminates $625M TIGIT Program as Clinical Data Falls Short of Expectations

GSK Terminates $625M TIGIT Program as Clinical Data Falls Short of Expectations

GSK has announced the discontinuation of its anti-TIGIT antibody program, belrestotug, following disappointing clinical trial results. The decision, made in conjunction with development partner iTeos Therapeutics, comes after an assessment of progression-free survival data failed to meet expectations in multiple studies.

NoahAI News5/14/2025
Ratio Therapeutics to Build Radiopharmaceutical Facility in Utah, Advancing the Growing Field of Nuclear Medicine

Ratio Therapeutics to Build Radiopharmaceutical Facility in Utah, Advancing the Growing Field of Nuclear Medicine

Ratio Therapeutics, a company specializing in radiopharmaceuticals, has announced plans to construct a new research and manufacturing facility in Salt Lake City, Utah. The move signals a significant expansion in the rapidly evolving field of nuclear medicine and highlights the increasing importance of radiopharmaceuticals in cancer treatment and diagnostics.

NoahAI News5/14/2025
Leap Therapeutics Announces Major Restructuring and Strategic Refocus

Leap Therapeutics Announces Major Restructuring and Strategic Refocus

Leap Therapeutics, a Massachusetts-based biotech company, has unveiled a significant restructuring plan and a strategic shift in its drug development focus. The company, facing what CEO Douglas Onsi described as a "difficult market environment," is taking decisive action to streamline operations and concentrate on its most promising assets.

NoahAI News5/14/2025
Cohere Health Secures $90M Series C Funding to Expand AI Applications in Healthcare

Cohere Health Secures $90M Series C Funding to Expand AI Applications in Healthcare

Cohere Health, a digital health company known for its prior authorization technology, has successfully raised $90 million in a Series C funding round. This significant investment will enable the company to broaden its artificial intelligence (AI) capabilities and address additional technological challenges faced by payers and providers in the healthcare industry.

NoahAI News5/14/2025
Appeals Court Reopens CRISPR Patent Dispute, Shaking Gene Editing Landscape

Appeals Court Reopens CRISPR Patent Dispute, Shaking Gene Editing Landscape

A federal appeals court has reignited the long-standing CRISPR patent controversy, potentially reshaping the intellectual property landscape for gene editing technologies. The decision, which challenges a previous ruling favoring the Broad Institute, has sent ripples through the biotech industry and raised questions about the future of CRISPR-based therapeutics.

NoahAI News5/14/2025
Dutch Biotech Azafaros Secures €132M Series B Funding for Late-Stage Trials of Brain-Penetrant Drug

Dutch Biotech Azafaros Secures €132M Series B Funding for Late-Stage Trials of Brain-Penetrant Drug

Azafaros, a Dutch biotech company, has successfully raised €132 million ($147 million) in a Series B funding round to advance its rare neurological disease drug, nizubaglustat, through two late-stage clinical trials. The substantial investment underscores growing interest in treatments for lysosomal storage disorders and highlights the potential of brain-penetrant therapies in addressing unmet medical needs.

NoahAI News5/14/2025
Galapagos Reverses Course on Company Split, Reevaluates Strategic Direction

Galapagos Reverses Course on Company Split, Reevaluates Strategic Direction

Belgian biotech firm Galapagos NV has announced a sudden change in its strategic plans, halting its previously announced intention to split the company into two separate entities. This unexpected development comes just five months after the initial split proposal and signals a significant shift in the company's direction under new leadership.

NoahAI News5/14/2025
AbbVie Secures $335M Deal with ADARx for Next-Gen siRNA Therapeutics

AbbVie Secures $335M Deal with ADARx for Next-Gen siRNA Therapeutics

AbbVie has entered into a significant collaboration with ADARx Pharmaceuticals, marking a major step forward in the development of small interfering RNA (siRNA) therapeutics. The deal, announced on May 14, 2025, involves an upfront payment of $335 million from AbbVie to ADARx, with the potential for additional billions in option-related fees, milestone payments, and royalties.

NoahAI News5/14/2025
Lilly's Zepbound Outperforms Novo's Wegovy in Weight Loss Efficacy and Safety

Lilly's Zepbound Outperforms Novo's Wegovy in Weight Loss Efficacy and Safety

Eli Lilly's obesity drug Zepbound (tirzepatide) has demonstrated superior weight loss efficacy and a comparable safety profile to Novo Nordisk's Wegovy (semaglutide) in a head-to-head clinical trial, potentially reshaping the competitive landscape of the rapidly growing obesity treatment market.

NoahAI News5/12/2025
Roche Invests Heavily in Global Manufacturing, Boosting Presence in US and China

Roche Invests Heavily in Global Manufacturing, Boosting Presence in US and China

Roche, the Swiss pharmaceutical giant, has announced significant investments in its manufacturing capabilities across multiple countries, with a particular focus on the United States and China. These strategic moves come as the pharmaceutical industry faces potential tariffs and increased pressure to strengthen domestic production.

NoahAI News5/12/2025
«1...64656667»